Krystal Biotech Inc (KRYS)

$156.88

+1.2

(+0.77%)▲

Market is closed - opens 7 PM, 29 Apr 2024

Insights on Krystal Biotech Inc

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 149.2%

Performance

  • $153.79
    $158.93
    $156.88
    downward going graph

    1.97%

    Downside

    Day's Volatility :3.23%

    Upside

    1.29%

    downward going graph
  • $82.09
    $189.97
    $156.88
    downward going graph

    47.67%

    Downside

    52 Weeks Volatility :56.79%

    Upside

    17.42%

    downward going graph

Returns

PeriodKrystal Biotech IncSector (Health Care)Index (Russel 2000)
3 Months
34.17%
0.5%
0.0%
6 Months
31.92%
11.7%
0.0%
1 Year
82.04%
6.2%
2.2%
3 Years
90.32%
13.5%
-23.0%

Highlights

Market Capitalization
4.5B
Book Value
$27.58
Earnings Per Share (EPS)
0.39
PE Ratio
399.18
Wall Street Target Price
188.5
Profit Margin
21.56%
Operating Margin TTM
7.45%
Return On Assets TTM
-8.83%
Return On Equity TTM
1.68%
Revenue TTM
50.7M
Revenue Per Share TTM
1.87
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-92.2M
Diluted Eps TTM
0.39
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
1.49
EPS Estimate Next Year
4.22
EPS Estimate Current Quarter
-0.38
EPS Estimate Next Quarter
-0.23

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Krystal Biotech Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
14
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 20.16%

Current $156.88
Target $188.50

Technicals Summary

Sell

Neutral

Buy

Krystal Biotech Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Krystal Biotech Inc
Krystal Biotech Inc
-10.62%
31.92%
82.04%
90.32%
371.76%
Moderna, Inc.
Moderna, Inc.
-1.15%
39.75%
-18.77%
-40.22%
304.34%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.56%
12.46%
14.48%
77.72%
159.17%
Novo Nordisk A/s
Novo Nordisk A/s
-2.8%
32.13%
52.48%
239.51%
414.16%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.96%
10.08%
23.01%
83.3%
130.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Krystal Biotech Inc
Krystal Biotech Inc
399.18
399.18
NA
1.49
0.02
-0.09
NA
27.58
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Krystal Biotech Inc
Krystal Biotech Inc
Buy
$4.5B
371.76%
399.18
21.56%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
304.34%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
159.17%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
414.16%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
130.08%
28.81
36.68%

Institutional Holdings

  • venBio Select Advisor LLC

    9.07%

  • Vanguard Group Inc

    8.61%

  • FMR Inc

    8.43%

  • Redmile Group, LLC

    7.08%

  • BlackRock Inc

    6.40%

  • State Street Corporation

    4.37%

Company Information

krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)

Organization
Krystal Biotech Inc
Employees
229
CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Industry
Health Technology

Discover More

FAQs